Weiss Multi Strategy Advisers LLC 89bio, Inc. Transaction History

Weiss Multi Strategy Advisers LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$6.66 - $16.03 $1.09 Million - $2.62 Million	163,669 Added 246.75%	230,000 $2.57 Million
Q3 2023 Nov 14, 2023	SELL	$15.06 - $19.41 $427,222 - $550,622	-28,368 Reduced 29.96%	66,331 $1.02 Million
Q2 2023 Aug 14, 2023	BUY	$14.15 - $22.03 $1.13 Million - $1.76 Million	79,957 Added 542.38%	94,699 $1.8 Million
Q1 2023 May 15, 2023	BUY	$10.48 - $16.94 $154,496 - $249,729	14,742 New	14,742 $225,000

158

108M

73.6K

1.19M

Ticker ETNB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,484,500
Market Cap $415M
Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...

Get notified when there are updates to the investment portfolio of Weiss Multi Strategy Advisers LLC, based on Form 13F filings with the SEC.

Stay updated on Weiss Multi Strategy Advisers LLC with notifications on news.